Catalyst Wire Dossier Catalyst Wire Dossier

Tasurgratinib (E7090)

Tasurgratinib · Eisai Co., Ltd
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tasurgratinib (E7090), covering 2026-01-23 to 2026-01-23. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants [Phase 1]

See pricing